Insulin biosimilar / Zimmerman Biotech - LARVOL DELTA

Oral glucose-lowering drugs in relation to initial choice of insulin in different parts of the world; Findings from the A1chieve study (ADA 2011) - Publish only abstract; A1chieve; P=NA, N=66,726; Baseline A1C in the basal, mealtime & premix insulin groups was 9.5 %, but higher (10.0 %) in those beginning a mealtime+basal regimen; Duration of diabetes was similar for people starting mealtime (7.2±5.7 yr) insulin alone or premix (7.9±6.0 yr), but longer for those starting basal alone (9.4±6.7 yr) or mealtime+basal (10.0±6.4 yr) insulin regimens; People in south Asia & north Africa were more likely to continue sulfonylureas (55% & 56%) than those in China (7%), people in China were also more likely to discontinue metformin

Clinical data • Diabetes

Satisfaction of Treatment Among Elderly Patients With Insulin Therapy - Emory, P4, N=56

Diabetes

Resolution of Type 2 Diabetes Mellitus: Intensive vs. Conventional Glycaemic Control After Obesity Surgery -

Imperial College London; P=NA, N=100;

CPEX`s Nasulin insulin therapy featured in an oral presentation and four abstracts at the Ninth Annual Diabetes Technology Meeting (Reuters) - Data from these studies provide important information on Nasulin’s ability to rapidly lower glucose following a meal and gain additional insight into the potential benefits Nasulin could offer to patients with diabetes

Data presentation • Diabetes

Insulin Infusion and Infectious Diabetic Foot Ulcers (IIIFU) -

Karolinska Institutet; P4, N=40;

Hospital management of hyperglycemia study of insulin glargine plus insulin lispro versus human regular insulin (HMH) (clinicaltrials.gov) - P3, N=266; Recruiting; Completion date: Sep ’12 → Jan ‘13

Diabetes